View the historical price chart for CLOV to analyze trends and spot opportunities. Use our interactive chart to compare past performance and make informed decisions.
Yes, CLOV stock appears to be a good buy in 2025 based on our comprehensive analysis.
Comprehensive analysis of whether CLOV stock is a good investment in 2025, including growth drivers, valuation metrics, risk factors, and analyst recommendations.
CLOV presents a mixed investment profile for 2025. The company shows strong growth drivers including healthcare sector momentum, though analyst price targets suggest 44.8% upside potential.
Analyst sentiment is generally positive with 8 buy ratings vs 1 sell ratings.
Investors should weigh the growth potential against the identified risks, particularly healthcare sector cyclicality, and consider their own risk tolerance and investment timeline.
Based on our comprehensive analysis of CLOV's financial metrics, growth prospects, valuation, analyst sentiment, and risk factors, we recommend a BUY. This recommendation considers the company's current fundamentals, market position, and future growth potential while accounting for identified risks and market conditions.
Based on revenue growth analysis and market trends, clov stock is projected to reach $7.35 by 2030, representing a 191.7% increase from the current price of $2.52.
Get detailed analyst targets, key factors, and comprehensive forecast analysis
Analyze financial statements and market position
Review price charts and technical indicators
Evaluate market and company-specific risks
Healthcare
Healthcare Plans
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligib...
Make buy/hold/sell decision with price targets
Get detailed step-by-step analysis, risk assessment, and investment strategies
1209 Orange Street, Wilmington, DE 19801
United States
Get detailed executive information, governance metrics, and comprehensive corporate data